Exclusive: Lee Ainslie’s Maverick Details Thesis For Biotech SectorMichelle Jones
Lee Ainslie's Maverick USA is up by about 32% year to date, although it was in the red for the second quarter. Over the last four years, the fund has boosted its exposure to the biotech sector from zero to the highest level in its history.
Maverick now holds seven different long positions in biotech companies. Ainslie . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.